Results from TUXEDO-3, a prospective multicentre open-label single-arm multicohort phase II study were recently published on The Lancet Oncology. TUXEDO-3 evaluated patritumab deruxtecan in 3 patient cohorts: 1. patients with metastatic breast cancer with untreated or progressing brain metastases after local treatment"; 2. "patients with advanced non-small cell lung cancer with untreated or progressing brain metastases after local treatment" 3. "patients with treatment-naive leptomeningeal disease (LMD) or LMD progressing after radiotherapy from any advanced solid tumour."
To read more about the TUXEDO-3 study, click here.
Sources mentioned:
- Bartsch R, Marhold M, Garde-Noguera J, et al. Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial . The Lancet Oncology 2025;26(11):1467-1478.
- Fuereder T, Garde-Noguera J, García-Mosquera JJ, et al. Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial . The Lancet Oncology 2025;26(11):1454-1466.
- Jerzak KJ, Leighl NB, Sahgal A. Systemic therapy for brain metastases: a changing landscape . The Lancet Oncology 2025;26(11):P1398-1400.
Active brain metastases are usually an exclusion in trials, so activity data in heavily pretreated breast cancer and NSCLC patients with brain disease is genuinely valuable. Crossing into the central nervous system has been the limiting factor for many antibody-drug conjugates, and any signal here deserves careful follow-up. Complex cases like this are often covered in discussions led by rohit gosain, especially where trial populations finally start to resemble the patients clinicians actually see.
ReplyDelete